FDA Approves Agios’ AQVESME™: A Historic Shift in Thalassemia Care

In a landmark decision for the rare disease community, the U.S. Food and Drug Administration (FDA) has approved AQVESME™ (mitapivat), developed by Agios Pharmaceuticals.¹ This oral medication is now the first and only therapy approved to treat anemia in adults across the full spectrum of the disease—including both alpha- and beta-thalassemia, and both transfusion-dependent and non-transfusion-dependent patients.²

Clinical Breakthrough: The ENERGIZE Trials

The FDA’s greenlight stems from two pivotal Phase 3 studies, ENERGIZE and ENERGIZE-T.³ These trials demonstrated that AQVESME significantly:

Boosts Hemoglobin: Patients saw a marked increase in the protein responsible for oxygen transport.
Reduces Transfusion Burden: A substantial drop in the frequency of required blood transfusions.⁴
Enhances Quality of Life: Patients reported a measurable reduction in chronic, debilitating fatigue.⁵

Safety & The REMS Requirement

While the approval is a triumph, it comes with specific safety mandates. Due to isolated cases of potential liver injury during clinical trials, the FDA has implemented a Risk Evaluation and Mitigation Strategy (REMS).⁶

Safety Protocols include:

Strict Monitoring: Baseline liver function tests are required before the first dose.⁷
Ongoing Surveillance: Regular blood work throughout the duration of treatment.
Provider Certification: Only healthcare providers enrolled in the REMS program can prescribe the drug.⁸

Strategic Market Position

Agios is already established in the rare blood disorder space with PYRUKYND® (also mitapivat) for pyruvate kinase deficiency.⁹ However, AQVESME™ will be the dedicated brand for the thalassemia market.

Feature	Details
Administration	Oral (Pill form)
Target Population	Adults with Alpha- or Beta-Thalassemia
Primary Benefit	Sustained hemoglobin increase
Market Status	First-in-class oral therapy

Voices from the Community

“This is a landmark moment. Many adults with this lifelong condition previously faced a severe lack of approved options.¹⁰ AQVESME offers a new path forward.” — Brian Goff, CEO of Agios Pharmaceuticals.¹¹

Ralph Colasanti, President of the Cooley’s Anemia Foundation, added that the approval provides “critical hope” for thousands of Americans who previously had to rely solely on blood transfusions and iron chelation therapy.